These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 19031633)

  • 1. [Contributions of the software La Clé Concerto in the implementation of the NKF-K/DOQI (National Kidney Foundation-Kidney/Dialysis Outcomes Quality Initiative) recommendations for the control of mineral and bone metabolism disorders in the patient with chronic renal failure].
    Ureña P
    Nephrol Ther; 2008 Sep; 4 Spec No 1():9-14, 20-35. PubMed ID: 19031633
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview.
    Bailie GR; Massry SG;
    Pharmacotherapy; 2005 Dec; 25(12):1687-707. PubMed ID: 16305288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Management of mineral and bone disease caused by chronic renal disease: what recommendations have contributed].
    Houillier P;
    Nephrol Ther; 2008 Sep; 4 Spec No 1():2-8, 15-9. PubMed ID: 19031626
    [No Abstract]   [Full Text] [Related]  

  • 4. Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism.
    González EA; Al-Aly Z; Martin KJ
    Semin Dial; 2005; 18(3):171-4. PubMed ID: 15934956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.
    Monge M; Shahapuni I; Oprisiu R; El Esper N; Morinière P; Massy Z; Choukroun G; Fournier A
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):326-36. PubMed ID: 16932454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. K/DOQI guidelines for bone metabolism and disease in chronic kidney disease patients: some therapeutic implications.
    Uribarri J;
    Semin Dial; 2004; 17(5):349-50. PubMed ID: 15461740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative.
    Am J Kidney Dis; 1997 Oct; 30(4 Suppl 3):S192-240. PubMed ID: 9339151
    [No Abstract]   [Full Text] [Related]  

  • 8. [Relationship between sevelamer HCl and vascular calcification].
    Uemura K; Kakuta T; Saito A
    Clin Calcium; 2007 Mar; 17(3):392-8. PubMed ID: 17339744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interprovincial differences in the achievement of K/DOQI targets of mineral metabolism in Canada.
    Lebner AC; Beard KM; Soroka SD; Cournoyer SH; Da Roza GA; Geary DF; Mendelssohn DC
    Nephrol Dial Transplant; 2011 Jan; 26(1):156-63. PubMed ID: 20667990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults.
    Bellorin-Font E; Ambrosoni P; Carlini RG; Carvalho AB; Correa-Rotter R; Cueto-Manzano A; Jara A; Jorgetti V; Negri AL; Olaizola I; Salusky I; Slatopolsky E; Weisinger JR; ;
    Nefrologia; 2013; 33 Suppl 1():1-28. PubMed ID: 23629678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K/DOQI gets to the heart of managing dyslipidemias in patients with CKD.
    Benner D
    Nephrol Nurs J; 2005; 32(3):337-8. PubMed ID: 16035475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questions.
    Patel TV; Singh AK
    Semin Nephrol; 2009 Mar; 29(2):105-12. PubMed ID: 19371801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic bone disease in chronic kidney disease.
    Martin KJ; González EA
    J Am Soc Nephrol; 2007 Mar; 18(3):875-85. PubMed ID: 17251386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic kidney disease-related mineral and bone disorders.
    Argilés A; Vanholder R
    Nephron Clin Pract; 2009; 112(3):c128-36. PubMed ID: 19390213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients.
    White CA; Jaffey J; Magner P
    Kidney Int; 2007 Feb; 71(4):312-7. PubMed ID: 17183248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program.
    Wazny LD; Raymond CB; Lesperance EM; Bernstein KN
    CANNT J; 2008; 18(2):36-41, 44-50; quiz 42-3, 51-2. PubMed ID: 18669010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone disease in uremia.
    Coburn JW
    Henry Ford Hosp Med J; 1983; 31(4):217-20. PubMed ID: 6674267
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical nutrition therapy in chronic kidney failure: integrating clinical practice guidelines.
    Beto JA; Bansal VK
    J Am Diet Assoc; 2004 Mar; 104(3):404-9. PubMed ID: 14993863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The spectrum of renal bone disease: introduction.
    LeBoff MS
    Semin Nephrol; 2009 Mar; 29(2):95-6. PubMed ID: 19371799
    [No Abstract]   [Full Text] [Related]  

  • 20. [SEN Guidelines. Recommendations of the Spanish Society of Nephrology for managing bone-mineral metabolic alterations in chronic renal disease patients].
    Torregrosa JV; Cannata Andia J; Bover J; Caravaca F; Lorenzo V; Martín de Francisco AL; Martín-Malo A; Martínez I; González Parra E; Fernández Giráldez E; Rodríguez Portillo M;
    Nefrologia; 2008; 28 Suppl 1():1-22. PubMed ID: 18338978
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.